Pharma-Bio Serv, Inc. (PBSV) research
Pharma-Bio Serv, Inc.- Sector
- Healthcare
- Industry
- Health Information Services
- Last price
- $0.50
- As of
Pharma-Bio Serv, Inc. (PBSV): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-09-14.
As of . Source: SEC EDGAR filings for PBSV. Method and limitations.
Share the PBSV intelligence card
See the full PBSV dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PBSV on one page. Preview it with sample data, then open it live with a free account.
Preview the PBSV dossierActive signals for PBSV
- lowEARNINGS_MISS
EPS $0.001 vs $0.0204 estimate, -0.02 on a near-zero consensus
- lowEARNINGS_MISS
Q3-2025: EPS $-0.009 vs $0.0306 estimate, -0.04 on a near-zero consensus
- lowEARNINGS_MISS
Q2-2026: EPS $0.01 vs $0.0306 estimate, -0.02 on a near-zero consensus
- lowEARNINGS_MISS
Q2-2026: EPS $0.004 vs $0.0306 estimate, -0.03 on a near-zero consensus
- lowEARNINGS_MISS
Q2-2026: EPS $-0.009 vs $0.0306 estimate, -0.04 on a near-zero consensus
FREE, NO ACCOUNT
Every signal on PBSV, as it fires
You are seeing 5 of 6 signals recorded on PBSV since 2026-06-02.
The five above landed across 4 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, PBSV
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
PBSV against its peers
PBSV's operating margin of -7.1% ranks in the 82nd percentile of 13 Health Information Services sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-01-31.
| Metric | PBSV | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 9.0M USD | 1.4M USD | 64 | 17 |
| Revenue YoY | n/a | -24.5% | n/a | 6 |
| Gross margin | 32.3% | 52.6% | 35 | 12 |
| Operating margin | -7.1% | -74.0% | 82 | 13 |
| Net margin | -1.1% | -91.9% | 83 | 14 |
| Return on equity | -0.8% | -112.3% | 86 | 10 |
Peers (18): MGRX, ZCMD, VYND, ACON, HCTI, BRGX, BFRG, CRVW, MITI, BEAT, ESSI, ONMD, WLSS, VSEE, MNDR, VASO, DOGP, DRIO. Left out: CMHSF (no annual filing), PAXH (period gap), OHCFF (no annual filing), RMHI (no annual filing), VRHI (no annual filing), DGNOF (no annual filing), RNLXY (period gap). Fiscal periods ending between 2025-06-30 and 2026-01-31. Every figure is one full fiscal year read from one annual filing (PBSV: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more PBSV signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to PBSVand get the insider, 13F, options, and confluence read in one view.